- Home
- ITGR vs GLPG Comparison
ITGR vs GLPG Comparison
Compare ITGR & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITGR | GLPG |
|---|---|---|
| Founded | 1970 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.2B |
| IPO Year | 2000 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ITGR | GLPG |
|---|---|---|
| Price | $86.06 | $34.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 4 |
| Target Price | ★ $86.67 | $31.33 |
| AVG Volume (30 Days) | ★ 546.2K | 124.5K |
| Earning Date | 02-19-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $1,831,074,000.00 | $336,643,201.00 |
| Revenue This Year | $9.58 | $1.76 |
| Revenue Next Year | N/A | $0.49 |
| P/E Ratio | $35.82 | ★ N/A |
| Revenue Growth | 9.54 | ★ 10.31 |
| 52 Week Low | $62.00 | $22.36 |
| 52 Week High | $146.36 | $37.78 |
Technical Indicators
Market Signals| Indicator | ITGR | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 60.72 | 60.17 |
| Support Level | $83.39 | $34.18 |
| Resistance Level | $87.39 | $35.06 |
| Average True Range (ATR) | 2.05 | 0.72 |
| MACD | -0.21 | -0.03 |
| Stochastic Oscillator | 64.02 | 70.65 |
Price Performance
Historical ComparisonAbout ITGR Integer Holdings Corporation
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.